NCT07190300 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT07190300
Title	TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) (TulmiSTAR-02)
Acronym	TulmiSTAR-02
Recruitment	Recruiting
Gender	male
Phase	Phase Ib/II
Variant Requirements	No
Sponsors	Novartis Pharmaceuticals
Indications	prostate cancer
Therapies	Darolutamide Abiraterone + Tulmimetostat Darolutamide + Tulmimetostat
Age Groups:	adult \| senior
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
Wichita Urology Group PA	RECRUITING	Wichita	Kansas	67226	United States	Details
Novartis Investigative Site	RECRUITING	Seoul		06591	South Korea	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT07190300Clinical Trial Detail